Wednesday, January 31, 2024

Andersen Expands Valuation Capabilities Across Latin America through Additions in Argentina, Chile, Colombia, and Mexico

 SAN FRANCISCO - Tuesday, 30. January 2024

(BUSINESS WIRE)--Andersen, the fastest-growing independent, multidisciplinary professional services organization in the world, has extended its valuation capabilities and team through the addition of collaborating firms in Argentina, Chile, Colombia, and Mexico. The announcement follows the launch of Andersen’s global valuation practice and the addition of valuation capabilities in Brazil last year. These additions bolster the organization’s rapidly growing platform in the region which already boasts tax and legal coverage in more than 18 countries throughout Latin America.

The new firms joining Andersen’s platform in Latin America include:

First Capital Group (Argentina) – Based in Buenos Aires, First Capital Group is a team of finance professionals with over 30 years of experience providing business and financial solutions, including valuation services.

Valoriza (Chile) – With offices in Santiago and Miami, Valoriza is an independent firm providing thorough and insightful valuations with a focus on corporate valuations and M&A for the mid-market.

Valuaciones de Chile (Chile) – Based in Santiago, Valuaciones de Chile provides independent valuation services focused on real estate, assets, and machinery and equipment.

Confianza (Colombia) – Located in Bogota, Confianza specializes in machinery and equipment appraisals, providing clients in Latin America with comprehensive support in their financial operations.

Giron Valuation Services (Mexico) – Operating out of Estado de México, Giron Valuation Services (GVS) is a team of professionals with extensive experience providing business valuations and financial advisory services to both local and global clients.

“Valuation is a significant area of growth for Andersen, and you can expect to see us rapidly expand our global valuation practice in other key markets throughout Latin America and globally,” said Mark L. Vorsatz, global chairman and CEO of Andersen.

“We’re proud to be working alongside these firms as we extend our global valuation service offering across Latin America,” added Sid Luckenbach, managing director of Andersen’s global valuation practice. “These new firms are a strong cultural fit for Andersen, sharing our commitment to independence, seamless client service, stewardship, and excellence.”

Andersen’s global valuation team works with companies, funds, high-net-worth individuals, and family offices to provide valuations of businesses, tangible and intangible assets, and complex securities for tax, financial reporting, and transaction advisory purposes. Andersen clients span a range of industries with diverse valuation needs around the globe.

“Latin America continues to be an exciting market for growth for us,” said Leonardo Mesquita, Andersen’s regional managing director for Latin America. "Our clients are increasingly requiring independent valuations throughout the region, and we look forward to meeting their valuation needs as one firm.”

Andersen’s global valuation practice has a presence in more than 25 countries across North America, Europe, Latin America, the Middle East, and Asia.

About Andersen:

Andersen Global is an international association of legally separate, independent member firms comprised of tax, legal, and valuation professionals around the world. Established in 2013 by U.S. member firm Andersen Tax LLC, Andersen Global now has more than 15,000 professionals worldwide and a presence in over 425 locations through its member firms and collaborating firms.


View source version on



Megan Tsuei

Andersen Global


AtkinsRéalis strengthens its advisory, planning and design services with strategic appointments in the Middle East

Dubai, United Arab Emirates - Wednesday, 31. January 2024

AtkinsRéalis (TSX: ATRL), a fully integrated professional services and project management company with offices around the world, has announced key leadership appointments to support its advisory, planning and design services business growth in the Middle East. The new appointments are set to strengthen the company’s regional footprint while meeting clients and projects’ evolving needs to achieve sustainable growth.


To help bring clients’ visions to life, AtkinsRéalis is investing in its design capabilities by establishing an architecture studio that brings together top-notch talent and embeds AI tools and purposeful design practices to create livable, sustainable and adaptable places fit for the future. This sees the appointment of Maxwell Connop as Regional Practice Lead, Architecture. He brings a wealth of over 30 years’ experience across the UK, Asia and the Middle East, and a broad portfolio of aviation, rail, hospitality and residential projects. Maxwell’s approach to design and architecture is underpinned by the core values of sustainability and creative digital tools to drive innovation and the long-term impact in the built environment.


In addition, Andre Mourinha has joined AtkinsRéalis as Regional Head of Masterplanning and Urban Design. With an extensive and dynamic career spanning more than 16 years, he has been at the forefront of pioneering award-winning projects in Europe, Asia, Africa, and the Middle East. Recognized for his exceptional leadership skills and commitment to design excellence and innovation, Andre’s method strikes a perfect balance between ingenuity and commercial viability.


“As the Middle East region continues to evolve and accelerate its decarbonization journey while building resilience, our clients increasingly demand integrated, sustainable, and technology-enabled design and masterplanning solutions to address the challenges of population growth and climate change,” commented Matthew Tribe, Managing director, Planning, Design and Engineering, Middle East & Africa at AtkinsRéalis. “Through our end-to-end capabilities, our integrated team of subject matter experts play a pivotal role in providing strategic guidance across the design and urban planning portfolio. The leadership team additions will not only build on our successful track record, but also boost the regional transformation journey towards shaping people-centric, smart, and sustainable environments fit for the future.”


AtkinsRéalis’ approach to providing seamless end-to-end capabilities in transport, infrastructure and buildings and places is further strengthened by establishing a dedicated Strategy and Advisory Business led by Johanna Staples, Regional Head of Advisory Services. With an international career spanning over 25 years, she has advised public and private sector clients on how to sustainably plan and execute their programs and projects across the built environment, transport and infrastructure industries. Since 2018, Johanna has led AtkinsRéalis’ regional advisory services growth, and her new role will be pivotal to integrating front-end advisory services and sustainable practices with the company’s core planning, design and engineering offerings.


Furthermore, Adam Crozier has been appointed Regional Head of Strategic Planning. With over 20 years’ experience in the UK, Europe, Asia and the Middle East, Adam has in-depth project expertise and knowledge in regional and city-scale development strategies, combining social, economic, environmental, and physical best practices to create purposeful urban places. Throughout his career, he’s led international multi-disciplinary practices towards achieving holistic outcomes and championing industry innovation.


In line with its commitment to supporting the decarbonization of the built environment, AtkinsRéalis has joined forces along with over 350 industry leaders as part of the World Green Building Council’s Open Letter initiative aimed at driving a unified call to action, reflecting the critical role of the sector in delivering climate change solutions and mitigation plans. The letter supports a high-level political announcement also endorsed at COP28 by 25+ countries, calling for ‘near-zero emission and resilient buildings as the new normal by 2030’. The company’s global ‘Engineering Net Zero’ program introduced DecarbonomicsTM, a data-driven solution that helps clients in the Middle East decarbonize their existing assets by making carbon visible across an entire asset portfolio and any stage of assets’ life cycle.


About AtkinsRéalis

Created by the integration of long-standing organizations dating back to 1911, AtkinsRéalis is a world-leading professional services and project management company dedicated to engineering a better future for our planet and its people. We create sustainable solutions that connect people, data and technology to transform the world's infrastructure and energy systems. We deploy global capabilities locally to our clients and deliver unique end-to-end services across the whole life cycle of an asset including consulting, advisory & environmental services, intelligent networks & cybersecurity, design & engineering, procurement, project & construction management, operations & maintenance, decommissioning and capital. The breadth and depth of our capabilities are delivered to clients in key strategic sectors such as Engineering Services, Nuclear, Operations & Maintenance and Capital. News and information are available at or follow us on LinkedIn.

Zeina Kourki

Senior Manager, External Communications, MEA APAC       

Boomi Secures Two Patents for AI Innovation

 CHESTERBROOK, Pa. - Wednesday, 31. January 2024 AETOSWire Print 

The company’s new technology patents challenge existing iPaaS paradigms, reinforcing Boomi’s innovation leadership in integration, automation, and AI

(BUSINESS WIRE)--Boomi™, the intelligent integration and automation leader, is proud to announce that it has been granted two new patents by the United States Patent and Trademark Office (USPTO) in the field of Artificial Intelligence (AI). These patents boost Boomi's total patent number to 36, underscoring the company's commitment to innovation and its ongoing efforts to push the boundaries of AI advancement.

The newly granted U.S. Patent No. 11,886,965, titled “Artificial-Intelligence-Assisted Construction of Integration Processes,” encompasses the underlying technology of features that allow Boomi’s customers to build integrations based on Boomi suggestions, including Shape Suggest, Quick Start, and more recently, Boomi AI. This innovation addresses the steep learning curve that users, both novice and expert, face when constructing integration processes on an integration platform.

Employing machine learning models – based on a Markov chain or various forms of graph neural networks – facilitates a predictive guidance system for users, enhancing the efficiency and effectiveness of constructing integration processes.

“Our patent award for ‘Artificial-Intelligence-Assisted Construction of Integration Processes’ stands as a notable innovation in the domain of integration platform as a service (iPaaS), and is a testament to the hard work and dedication of our talented team of engineers, scientists, and innovators,” said Ed Macosky, Chief Product and Technology Officer at Boomi. “The contributions through this patent fundamentally challenge the existing paradigms inherent when constructing integration processes. Before this innovation, the construction of integration processes largely relied on the user's expertise and manual inputs using a drag and drop UI, which could be time-consuming and prone to errors, especially for those new to the platform. This AI-driven approach has transitioned construction of integration processes to an intelligent, predictive, and guided task.”

Boomi was also recently granted U.S. Patent No. 11,847,167, titled “System and Method for Generation of Chat Bot System with Integration Elements Augmenting Natural Language Processing and Native Business Rules.” This patent is for a technology solution built on the Boomi platform that creates a series of templatized processes and designs. This allows Boomi customers to build hybrid chatbots that combine rules-based connectivity, natural language processing, Boomi logic, and AI technologies to triage and route requests coming into the chatbot. This technology helped lay the foundation for Retrieval Augmented Generation and demonstrates Boomi’s early innovations in applying AI to integration.

Macosky added, “Achieving these patents reaffirms our commitment to continuous innovation and underscores our position as a leader in the industry. We are excited about the potential impact our AI patents will have for our customers and partners, and we look forward to continuing our mission of driving transformation through intelligent integration and automation.”

Additional Resources

Learn more about the Boomi platform

Explore the Boomiverse Community

Follow Boomi on X (Twitter), LinkedIn, Facebook, and YouTube

About Boomi

Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit

© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.


View source version on




Kristen Walker

Global Corporate Communications


AGCO Launches FarmerCore to Bring the Dealer Experience Directly to the Farm


 (BUSINESS WIRE)--AGCO (NYSE: AGCO), a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology, today announced the launch of FarmerCore, a transformative global initiative to deliver a next-generation farmer and dealer experience. The launch of the new end-to-end distribution model is a significant milestone in advancing AGCO’s Farmer-First strategy and solidifying its commitment to helping farmers across the globe become more profitable, productive and sustainable.

This press release features multimedia. View the full release here:

FarmerCore revolutionizes sales and service using tools that put dealers in closer proximity – onsite and online – to farmers. From product research to in-season uptime, the program develops and integrates digital and physical elements across the purchasing journey and product ownership lifecycle to create a leading on-farm offering.

“AGCO’s strategy remains focused on putting the farmer at the center of everything we do,” said Eric Hansotia, Chairman, President and CEO of AGCO. “The FarmerCore initiative further solidifies our pledge to prioritize farmers, blending physical and digital experiences to build brand loyalty and deepen customer engagement. Ultimately, we’re going to bring our entire business to the farmer through digital tools, service trucks, local parts access and more in partnership with AGCO’s global dealer network.”

FarmerCore is built on three pillars: the on-farm mindset, smart network coverage and digital engagement. The on-farm mindset positions dealers to meet customers’ needs at every stage of the ownership journey. Smart network coverage de-emphasizes the one-size-fits all outlet approach, moving toward a hub-and-spoke model that adds “light” retail outlets, service centers and parts-only locations. Digital engagement gives farmers 24/7 online access to sales and support, including online parts purchasing, dealer digital storefronts, online configurators and more.

Many AGCO dealerships already deploy aspects of the FarmerCore program, including mobile service fleets, alternative format outlets (e.g., parts-only stores) and digital tools to enhance customer support. In fact, the FarmerCore model has proven successful at the regional level through AgRevolution, an AGCO-owned, full-line agricultural equipment dealer serving farmers in Kentucky, Illinois and Indiana.

“We provide farmers with an outstanding on-farm experience that spans the entire ownership journey,” said Stacy Anthony, CEO of AgRevolution. “Our farmer-first mentality, combined with implementing FarmerCore’s assets, enables greater engagement across our region and helps us deliver exceptional customer outcomes and value. I am excited at the unlimited potential this innovative, farmer-first model will deliver to AGCO’s dealer network and farmers around the world.”

With FarmerCore, mobile assets bring buying and servicing to the farm. While dealership locations will continue to anchor farmer support in local communities, mobile and digital channels allow farmers to engage on their terms.

FarmerCore will be implemented in close partnership with AGCO’s global dealer network and will become a leader in ag machinery support, across every aspect of the ownership lifecycle. The program launches globally this year in select North and South America dealer organizations, with continued expansion throughout 2024.

About AGCO

AGCO (NYSE: AGCO) is a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology. AGCO delivers customer value through its differentiated brand portfolio including core brands like Fendt®, GSI®, Massey Ferguson®, Precision Planting® and Valtra®. Powered by Fuse® smart farming solutions, AGCO’s full line of equipment and services helps farmers sustainably feed our world. Founded in 1990 and headquartered in Duluth, Georgia, USA, AGCO had net sales of approximately $12.7 billion in 2022. For more information, visit For company news, information, and events, please follow us on X: @AGCOCorp. For financial news on X, please follow the hashtag #AGCOIR.



Aryn Drawdy
Corporate Communications Director

Climeworks and Svante Collaborate in Development and Supply for Direct Air Capture



  • Climeworks and Svante have signed a collaboration and supply agreement to further advance commercial-scale solutions for direct air capture.
  • Svante will provide Climeworks with contactor blocks incorporating first-of-its-kind filter technology.
  • Both companies agree to collaborate on three major CO2 removal projects in a critical step toward developing direct air capture hubs in the U.S. capable of capturing megatons of CO2.


(BUSINESS WIRE)--Climeworks has signed a collaboration and supply agreement with Svante Technologies Inc. (Svante), a leading carbon capture and removal solutions provider. The companies agreed to jointly plan the supply of Svante’s contactor blocks for three major Climeworks projects, intending to lead to a commercial-scale supply agreement, whereby Climeworks would purchase Svante’s contactor blocks for its planned megaton direct air capturing hubs in the US.

The US Department of Energy selected Climeworks to develop three of these hubs, in Louisiana, California, and North Dakota, making the company eligible for a total of more than USD 600 million in government funding.

Combined forces for global carbon removal

The collaboration allows both partners to agree on intermediate goals, and to jointly proceed to the next phase of development. “Delivering large-scale direct air capture required us to approach this collaboration with flexibility on the development of project specifications while retaining rigorous accountability for the success of the overall project,” says Claude Letourneau, President and CEO of Svante. “We’ve been closely collaborating with Climeworks over the past three years, and because of that proximity, we felt comfortable entering into this kind of arrangement. The combination of our advanced technologies represents a significant step forward in the nascent direct air capture industry, playing a critical role in meeting the world’s net-zero ambitions.”

Svante is in the final stages of building its commercial filter manufacturing facility, The Centre of Excellence for Carbon Capture and Removal, in Vancouver, BC, Canada. The Centre is equipped to supply both the industrial point source post-combustion carbon capture market and the direct air capture market. Svante has anticipated and prepared for the event where the agreement with Climeworks takes up a significant portion of the Centre’s capacity and has secured additional coating capacity with its partner, 3M.

Best-in-class technology for Climeworks’ large-scale direct air capture projects

With the extended collaboration, Climeworks secures best-in-class technology supporting its scale-up journey. A crucial part of the direct air capture process involves filter material trapping CO2 from the ambient air, and Svante’s filter technology will further enhance the performance of the carbon dioxide capturing process.

“We are focusing on the massive growth of our carbon removal technology to create climate impact,” says Jan Wurzbacher, Co-Founder and Co-CEO of Climeworks. “Svante is one of the key players in the ecosystem to support us in our journey to scale to a gigaton capacity.”

About Svante

Svante is a purpose-driven, leading carbon capture and removal solutions provider. The Vancouver, Canada-based company manufactures nanoengineered filters and modular rotary contactor machines that capture and remove CO2 from industrial emissions and the air in an environmentally responsible manner. Svante is on the 2024 Global Cleantech 100, the XPRIZE Foundation’s XB100 – World’s Top 100 Deep Tech Companies and was ranked second among private companies in the Corporate Knights’ Future 50 Fastest Growing Sustainable Companies. For more information, visit and follow Svante on LinkedIn at

About Climeworks

Climeworks is the global leader in carbon dioxide removal (CDR) as a service via direct air capture (DAC) technology, empowering companies to advance their net zero roadmaps and fight climate change. Founded by engineers Christoph Gebald and Jan Wurzbacher in 2009, Climeworks is on a journey to climate impact at scale with integrity at its core and a focus on high-quality, permanent carbon removals.

Climeworks is spearheading the DAC industry globally, with the world’s only commercial DAC facility combined with storage installation in operation, modular CO2 collectors designed for scalability, and facilities running on renewable energy. Their growing customer base counts over 160 companies, including multinationals such as Microsoft, BCG, UBS, and Swiss Re.

At Orca, Climeworks’ DAC facility in Iceland, the CO2 is permanently removed from the air by capturing and geologically storing it for thousands of years with Climeworks’ underground mineralization partner Carbfix. The CDR services delivered from Orca are verified by independent 3rd party DNV.



For media inquiries:
Colleen Nitta
Director, Marketing & Communications

‘World’s Most Romantic Building:’ Empire State Building Celebrates Valentine’s Day with NYC's Most Romantic Date Experience, Engagement Package, and Film Screenings

NEW YORK - Wednesday, 31. January 2024

Special screenings of ‘Clueless’ and ‘Sleepless in Seattle’; Engagement Package on the Observation Deck; and $10k Over-the-Top Valentine’s Day Dinner on a Private 102nd Floor

(BUSINESS WIRE)--Celebrate the most romantic day of the year at the “World’s Most Romantic Building.” The Empire State Building (ESB) – the number one attraction in the U.S. by Tripadvisor travelers for two consecutive years – announced today that it will host themed movie screenings; offer an over-the-top, bucket list Valentine’s Day date for one lucky couple; and provide a special engagement package for couples who plan to tie the knot this February.

Empire for Two – This year, one lucky couple can book the Empire State Building’s first ever private Valentine’s Day dining experience, that for a $10k price tag gives them access to the entire 86th Floor Observatory all to themselves, as well as a three-course dinner with wine pairing high atop the exclusive 102nd Floor, that is also closed for the entirety of the date. Curated and prepared by the head chef at STATE Grill and Bar – the Empire State Building’s signature restaurant on ground level – dishes include options like lump crab with caviar, porcini crusted filet mignon, and a decadent chocolate cake, accompanied by a live musician and themed decor. Before dinner, the couple will embark on a private tour of the Empire State Building with Champagne. The lavish Empire for Two ticket package is available for Feb. 14 at 8:30 p.m. and must be reserved by Feb. 12.

“As IF!” – Gather your girlfriends this Galentine’s Day for a one-time screening of the quotable comedy “Clueless” on the Empire State Building Observatory’s 80th Floor on Feb. 13. Fans will enjoy drinks and snacks from Culture POP, Dylan’s Candy Bar, and Rob’s Backstage Popcorn included with their ticket. Mixologists will shake up complimentary espresso martinis – courtesy of the newly opened, 23,000 square foot Starbucks Reserve® located at the base of the building – for guests to sip on with the movie before they take in the views from the 86th and 102nd Floor Observatories.

“It’s a Sign” – Channel the romance of “Sleepless in Seattle” – the classic ‘90s love story that features scenes filmed at the “World’s Most Romantic Building” – in a special screening on Feb 14. Guests will enjoy the film screening on the building’s 80th Floor with complimentary drinks and snacks from Culture POP, Dylan’s Candy Bar, Rob’s Backstage Popcorn included with their ticket. In a nod to their deep Seattle heritage, Starbucks Reserve® will serve complimentary espresso martinis to guests before they recreate the movie magic on the 86th and 102nd Floor Observatories.

Happily Ever Empire – Toast to forever with ESB’s exclusive engagement experience this February. The Happily Ever Empire package includes an exclusive guided tour of the Observatory Experience; a private, roped-off corner of the 86th Floor Observatory to pop the question; and a bottle of Champagne to toast to your “yes!”

Love Lights – On Feb. 14, the Empire State Building’s world-famous tower lights will shine in a pink heartbeat in its annual Valentine’s Day gift to New York City. Text CONNECT to 274-16 to receive real-time information about the Empire State Building’s tower lights.

“There is no better backdrop than the Empire State Building’s unparalleled views as you celebrate love this Valentine’s Day,” said Jean-Yves Ghazi, president of the Empire State Building Observatory. “We are excited to offer the exclusive opportunity for one couple to have our iconic Observatory all to themselves in New York City’s most romantic date.”

The Empire State Building Observatory Experience recently underwent a $165 million reimagination that features an interactive museum with nine galleries, brand-new bespoke Observatory host uniforms, and iconic Observatories on the 86th and 102nd Floors.

Hi-res imagery can be downloaded here. More information about the Empire State Building and tickets can be found online.

About the Empire State Building

The Empire State Building, the “World's Most Famous Building," owned by Empire State Realty Trust, Inc. (ESRT: NYSE), soars 1,454 feet above Midtown Manhattan from base to antenna. The $165 million reimagination of the Empire State Building Observatory Experience creates an all-new experience with a dedicated guest entrance, an interactive museum with nine galleries, and a redesigned 102nd Floor Observatory with floor-to-ceiling windows. The journey to the world-famous 86th Floor Observatory, the only 360-degree, open-air observatory with views of New York and beyond, orients visitors for their entire New York City experience and covers everything from the building's iconic history to its current place in pop culture. The Empire State Building Observatory Experience welcomes millions of visitors each year and was declared "America's Favorite Building" by the American Institute of Architects, the world's most popular travel destination by Uber, the #1 attraction in the US for the second year in a row in Tripadvisor’s 2023 Travelers’ Choice Awards: Best of the Best, and the #1 New York City attraction in Lonely Planet’s Ultimate Travel List.

Since 2011, the building has been fully powered by renewable wind electricity, and its many floors house a diverse array of office tenants such as LinkedIn and Shutterstock, as well as retail options like STATE Grill and Bar, Tacombi, and Starbucks. For more information and Observatory Experience tickets visit or follow the building's Facebook, X (formerly Twitter), Instagram, Weibo, YouTube, or TikTok.

Source: Empire State Realty Trust, Inc.

Category: Observatory


View source version on





Empire State Realty Trust

Jamie Steinberg


SLB Reaffirms 2024 Financial Guidance

HOUSTON - Wednesday, 31. January 2024 AETOSWire

Company remains confident in the strength and longevity of the cycle

(BUSINESS WIRE)--SLB (NYSE: SLB) today announced that it is reaffirming its full-year 2024 financial guidance.

“We acknowledge the decision by Saudi Aramco to maintain its Maximum Sustainable Capacity (MSC) at 12 million barrels per day (MMBD), and not to continue increasing MSC to 13 MMBD,” said SLB Chief Executive Officer Olivier Le Peuch. “We continue to work very closely with Saudi Aramco, and our understanding is that all ongoing oil and gas projects remain intact and that only two offshore oil increment projects not yet started will be suspended.”

“Our forecast for significant growth for 2024 in the Kingdom remains intact. Looking ahead, the combination of our revenue mix in the Kingdom, which is weighted toward onshore and the expanding gas market, and our unique market position in other countries in the Middle East will continue to support the multi-year growth cycle in the region.”

“As we shared during our most recent earnings release, global energy demand continues to increase, and international production is expected to play a key role in meeting supply through the end of this decade. Given this, we are confident in the strength and longevity of this cycle through 2024 and beyond.”

About SLB

SLB (NYSE: SLB) is a global technology company that drives energy innovation for a balanced planet. With a global footprint in more than 100 countries and employees representing almost twice as many nationalities, we work each day on innovating oil and gas, delivering digital at scale, decarbonizing industries, and developing and scaling new energy systems that accelerate the energy transition. Find out more at

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws — that is, statements about the future, not about past events. Such statements often contain words such as “expect,” “may,” “can,” “estimate,” “intend,” “anticipate,” “will,” “potential,” “projected" and other similar words. Forward-looking statements address matters that are, to varying degrees, uncertain, such as forecasts or expectations regarding the deployment of, or anticipated benefits of, SLB’s new technologies and partnerships; statements about goals, plans and projections with respect to sustainability and environmental matters; forecasts or expectations regarding energy transition and global climate change; and improvements in operating procedures and technology. These statements are subject to risks and uncertainties, including, but not limited to, the inability to achieve net-negative carbon emissions goals; the inability to recognize intended benefits of SLB’s strategies, initiatives or partnerships; legislative and regulatory initiatives addressing environmental concerns, including initiatives addressing the impact of global climate change; the timing or receipt of regulatory approvals and permits; and other risks and uncertainties detailed in SLB’s most recent Forms 10-K, 10-Q and 8-K filed with or furnished to the U.S. Securities and Exchange Commission. If one or more of these or other risks or uncertainties materialize (or the consequences of such a development changes), or should underlying assumptions prove incorrect, actual outcomes may vary materially from those reflected in our forward-looking statements. The forward-looking statements speak only as of the date of this press release, and SLB disclaims any intention or obligation to update publicly or revise such statements, whether as a result of new information, future events or otherwise.


View source version on




Josh Byerly

Vice President of Communications

Moira Duff

Director of External Communications


Tel: +1 (713) 375-3407



James R McDonald

SVP of Investor Relations & Industry Affairs

Joy V. Domingo

Director of Investor Relations


Tel: +1 (713) 375-3535


SLB and Equinor Drill Most Autonomous Well Section To-Date


SLB digital drilling solutions enabled Equinor to implement autonomous drilling at its Peregrino C platform in Brazil

(BUSINESS WIRE)--SLB (NYSE: SLB) today announced a significant step toward fully autonomous drilling operations at Equinor's Brazilian Peregrino C platform. SLB digital technologies for surface automation, autonomous on-bottom drilling, and directional drilling were combined to enable 99% of a 2.6-kilometer section to be drilled in autonomous control mode. Over a five-well program, a 60% increase in rate of penetration was achieved, resulting in faster well delivery while reducing cost and carbon emissions.

“This is an exciting milestone in the journey toward fully autonomous drilling operations,” said Jesus Lamas, President of Well Construction, SLB. “By leveraging AI and integrating advanced digital workflows, customers are realizing improved safety and performance through digital transformation, making drilling more consistent and efficient, and improving the carbon footprint of their operations.”

Multidisciplinary experts collaborated to design and implement interconnected autonomous workflows, enabling the system to seamlessly drill the section. On the rig floor, manual pipe handling and equipment sequencing tasks were automated with DrillPilot™ software. On-bottom drilling performance was maximized using AI-driven technology in the DrillOps™ automation solution. Neuro™ autonomous solutions determined the optimum trajectory and delivered the well plan, adjusting steering sequences and drilling parameters to reach the target as designed by the DrillPlan™ coherent well construction planning solution.

The DrillOps and DrillPlan solutions are cloud-based applications on the Delfi™ digital platform. The platform combines apps, AI, physics-based science and free-flowing data to accelerate and improve exploration, development, drilling, production, and new energy operations.

About SLB

SLB (NYSE: SLB) is a global technology company that drives energy innovation for a balanced planet. With a global footprint in more than 100 countries and employees representing almost twice as many nationalities, we work each day on innovating oil and gas, delivering digital at scale, decarbonizing industries, and developing and scaling new energy systems that accelerate the energy transition. Find out more at

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws — that is, statements about the future, not about past events. Such statements often contain words such as “expect,” “may,” “can,” “estimate,” “intend,” “anticipate,” “will,” “potential,” “projected" and other similar words. Forward-looking statements address matters that are, to varying degrees, uncertain, such as forecasts or expectations regarding the deployment of, or anticipated benefits of, SLB’s new technologies and partnerships; statements about goals, plans and projections with respect to sustainability and environmental matters; forecasts or expectations regarding energy transition and global climate change; and improvements in operating procedures and technology. These statements are subject to risks and uncertainties, including, but not limited to, the inability to achieve net-negative carbon emissions goals; the inability to recognize intended benefits of SLB’s strategies, initiatives or partnerships; legislative and regulatory initiatives addressing environmental concerns, including initiatives addressing the impact of global climate change; the timing or receipt of regulatory approvals and permits; and other risks and uncertainties detailed in SLB’s most recent Forms 10-K, 10-Q and 8-K filed with or furnished to the U.S. Securities and Exchange Commission. If one or more of these or other risks or uncertainties materialize (or the consequences of such a development changes), or should underlying assumptions prove incorrect, actual outcomes may vary materially from those reflected in our forward-looking statements. The forward-looking statements speak only as of the date of this press release, and SLB disclaims any intention or obligation to update publicly or revise such statements, whether as a result of new information, future events or otherwise.



Moira Duff – Director of External Communications
Tel: +1 (713) 375-3407

James R. McDonald – SVP of Investor Relations & Industry Affairs
Joy V. Domingo – Director of Investor Relations
Tel: +1 (713) 375-3535

Quanta System unveils the latest breakthrough technology drawn on its picosecond laser heritage: VarioPulse Technology®, the next-level device for the next-level experts

 (BUSINESS WIRE)--Quanta System proudly opens the door to the New Year by unleashing the ultimate innovation in the picosecond laser technologies: Discovery PICO with VarioPulse Technology®. An unprecedented level of precision and versatility in a device that allows you to select the picosecond pulse-duration to personalize the treatments to meet the unique needs of each person.

Quanta System has always been committed to follow the evolving needs of the market and to listen and understand the needs of its customers. Discovery PICO VarioPulse Technology® represents a significant leap forward in the world of aesthetic medicine.

Featuring Pico Boost technology that can deliver up to 1.8GW of laser power perfectly controlled by the VarioPulse Technology®, this next-generation device welcomes you to 3 cutting-edge customized treatments that are precisely designed to perform tattoo removal and skin revitalization at their best.

Pico Tune-Ink, the adaptable treatment that removes tattoo ink of a wide variety of colour and complexity;

Pico Filling, the no down-time treatment that revitalizes the skin from within and improve its appearance;

Pico Plasma, the all round skin remodeling treatment that targets scars and acne scars.

Commenting on this major launch, Girolamo Lionetti, CEO of Quanta System, expresses his excitement, "We are thrilled to bring this new technology to the aesthetic world. Our primary goal of improving people's quality of life is greatly enhanced by continuing to work alongside our valued partners, the physicians, and providing patients with more and more customized treatments.”

This is just the first step of a new era laser roadmap focused on delivering the superior user experience and patient satisfaction that the market has been waiting for.

For more information about Discovery PICO VarioPulse Technology®, visit our website or come to discover it in person at IMCAS Booth U322 Level 3 - February 1st -3rd 2024.

About Quanta System

For almost forty years Quanta System, a 100% Italian company distributed worldwide, is the reference point for the research, designing and manufacture of state-of-the-art laser systems for surgery, dermatology and aesthetic medicine and the conservation of art works.

In 2004 the company joins El.En. SpA, leader on the laser market listed on the Euronext STAR Milan ("STAR") of the Italian Stock Exchange and a partner of reference for health facilities, Institutions and Entities engaged in scientific and research projects at a global level.

Designed to be used by doctors, specialised operators and restorers, today the Quanta System lasers represent the "Gold Standard" thanks to a wide range of applications.

The laser systems are entirely manufactured in Italy: from Research & Development to production, the entire process takes place in the company's headquarters in Samarate (in the province of Varese).

Quanta System is a trusted partner, day in day out, of all doctors in every part of the world thanks to its ability to listen, its straightforward debates and the creation of new systems that increasingly meet the real needs of professionals so they can provide better care for their patients.

A constantly evolving company that has managed to update its production so that it has always managed to satisfy the developing needs of its time, without losing sight of its primary objective: contributing to the improvement of people's quality of life.


View source version on



Carolina Crepaldi –

Nubis Communications and Alphawave Semi Showcase First Demonstration of Optical PCI Express 6.0 Technology

 NEW PROVIDENCE, N.J. & TORONTO, Ontario - Wednesday, 31. January 2024 AETOSWire 

Extended link lengths to enhance the scalability of Artificial Intelligence and Machine Learning (AI/ML) clusters

NEW PROVIDENCE, N.J. & TORONTO, Ontario--(BUSINESS WIRE)--Nubis Communications, Inc., provider of low-latency high-density optical inter-connect (HDI/O), and Alphawave Semi (LN: AWE), a global leader in high-speed connectivity and compute silicon for the world’s technology infrastructure, today announced their upcoming demonstration of PCI Express 6.0 technology driving over an optical link at 64GT/s per lane. Data Center providers are exploring the use of PCIe over Optics to greatly expand the reach and flexibility of the interconnect for memory, CPUs, GPUs, and custom silicon accelerators to enable more scalable and energy-efficient clusters for Artificial Intelligence and Machine Learning (ML/AI) architectures.

This press release features multimedia. View the full release here:

Nubis Communications and Alphawave Semi will be showing a live demonstration in the Tektronix booth at DesignCon, the leading conference for advanced chip, board, and system design technologies. An Alphawave Semi PCIe Subsystem with PiCORE Controller IP and PipeCORE PHY will directly drive and receive PCIe 6.0 traffic through a Nubis XT1600 linear optical engine to demonstrate a PCIe 6.0 optical link at 64GT/s per fiber, with optical output waveform measured on a Tektronix sampling scope with a high-speed optical probe.

Optical transmission technology can be leveraged to greatly extend link distances at the same bandwidths compared with copper cables, supporting the larger cluster sizes needed to support ever-larger AI/ML servers distributed over multiple nodes, and enabling innovation in new disaggregated network architectures. The Nubis XT1600 optical engine supports up to 16 lanes of high-density PCIe Gen 6.0 or 100 Gbps/lane Ethernet optical connectivity without incorporating retimers.

“Our high level of integration with 16 lanes full-duplex in a single low-power, low-latency optical engine is a great match to the maximum bandwidth of PCIe x16 for next-generation compute and storage deployments,” said Scott Schube, VP of Marketing at Nubis Communications. “Our demonstration of the Nubis XT1600 linear optical engine and Alphawave Semi’s PCIe 6.0 Controller and PHY IP showcases the viability of a PCIe® 6.0 x8 link over optical fiber at 64 GT/s.”

“AI applications are reshaping data center networks, with hyperscalers deploying increasingly large clusters of disaggregated servers distributed over longer distances. This shift has generated heightened interest in PCIe over Optics among several of our customers,” said Tony Chan Carusone, CTO at Alphawave Semi. “Through our collaboration with Nubis, we’re pleased to demonstrate how we’re leveraging Alphawave Semi’s leadership in connectivity IP and silicon to enable PCIe optical connectivity solutions that accelerate high-performance AI computing and data infrastructure.”


The Nubis XT1600™ linear optical engine is available now for sampling, please contact via

More on Alphawave Semi’s PCIe Portfolio: Alphawave Semi’s PCI-Express Solution

About Nubis Communications

Nubis innovates across photonics, electronics, packaging, and manufacturing to create optics with significantly better scalability, density, and power efficiency than existing solutions, breaking the I/O wall in data centers and enabling more advanced computing, AI, and machine learning. For more information visit

XT-1600, HDI/O, and the Nubis Cloud Logo are trademarks of Nubis Communications.

About Alphawave Semi

Alphawave Semi is a global leader in high-speed connectivity and compute silicon for the world’s technology infrastructure. Faced with the exponential growth of data, Alphawave Semi’s technology services a critical need: enabling data to travel faster, more reliably and with higher performance at lower power. We are a vertically integrated semiconductor company, and our IP, custom silicon, and connectivity products are deployed by global tier-one customers in data centers, compute, networking, AI, 5G, autonomous vehicles, and storage. Founded in 2017 by an expert technical team with a proven track record in licensing semiconductor IP, our mission is to accelerate the critical data infrastructure at the heart of our digital world. To find out more about Alphawave Semi, visit:

Alphawave Semi and the Alphawave Semi logo are trademarks of Alphawave IP Group plc. All rights reserved.


View source version on




Contact for Nubis

Karen Liu

Contact for Alphawave Semi

Gravitate PR for Alphawave Semi

DigiLens Expands Technology Ecosystem with Leading Electronics System and Design (ESDM) Manufacturer Kaynes Technology India Limited as it Prepares for Global Scale

 DigiLens and Kaynes join forces to revolutionize Augmented Reality and mobile computing in APAC, and to manufacture scalable solutions for commercial, industrial, and defense markets in India

(BUSINESS WIRE)--DigiLens Inc., a leading nanotechnology innovator in waveguide display technologies and headworn smartglasses, announces a collaborative partnership with India-based Kaynes Technology India Limited to scale waveguide manufacturing. Kaynes Technology, a leader in electronic component manufacturing for the space research, defense, aerospace, railway, healthcare, automotive, and other commercial sectors, is strategically positioned as a DigiLens licensee to scale waveguide manufacturing to aid in the delivery of DigiLens’ flagship Augmented Reality (AR) device, the DigiLens ARGO™, in the Indian market. Kaynes Technology and DigiLens will collaborate through Kaynes Semicon Pvt Ltd, a 100% subsidiary of Kaynes Technology, at their Green Field facility in Hyderabad.

DigiLens’ optical platform allows OEMs to create customizable, cost-effective waveguide-based AR experiences for both enterprise and consumer applications. DigiLens’ optics are unique — they are manufactured from a proprietary photopolymer and low-cost holographic manufacturing process, which is more cost-effective than any other waveguide displays on the market.

“We are excited to be working with Kaynes Technology because of their advanced manufacturing and design presence in India. Augmented Reality glasses have started to scale in the market and DigiLens along with its licensed waveguide partners will be ready to deliver the highest-performing waveguides in the world,” says DigiLens CEO Chris Pickett. “Commercial delivery of AR smartglasses need these critical components from a global ecosystem of partners at a low cost and a high manufacturing yield to ensure success. Kaynes Technology’s existing footprint and market presence will help accelerate this adoption and enable new markets for both our companies.”

With a nearly $60 billion total addressable market growing to $280 billion by the end of 2030 at a compound annual growth rate of 34%, and some of the biggest technology companies like Meta, Google, and Apple committing an estimated $75 billion combined market investment, the DigiLens and Kaynes partnership represents a massive opportunity in the industry’s fastest-growing market, Asia.

“We are very excited about joining the Augmented Reality revolution and to supporting scaled manufacturing of the next generation of optical waveguides with DigiLens’ nanotechnology,” states Founder & Managing Director of Kaynes Technology, Mr. Ramesh Kannan. “This partnership greatly advances our initiatives towards advanced manufacturing in India and opens a new part of the world to deliver on the future of mobile compute. We are investing in building a world-class OSAT facility in Hyderabad, Telangana, where we will be manufacturing ‘Made in India’ waveguides and light engines for ARGO devices, as well as supplying high-yield waveguide manufacturing to satisfy the demand in global markets. We welcome DigiLens to the Kaynes family of companies, and we are looking forward to exceptional growth in this category.”

Through this partnership, DigiLens will significantly expand their footprint in APAC by bringing marquee products to the commercial, industrial, and defense markets in India. Together with Kaynes Technology, they will develop joint initiatives to deliver ARGO and other DigiLens products for AR, providing cutting-edge solutions to industry workforce challenges and driving innovation in manufacturing in India and the broader global market.

About Kaynes Technology

Kaynes Technology India Limited is a publicly listed Mysore-based integrated electronics manufacturer with capabilities across the entire spectrum of ESDM services. Kaynes has over three decades of experience in providing Conceptual Design, Process Engineering, Integrated Manufacturing, and Life Cycle Support for major players in the Automotive, Industrial, Aerospace and Defense, Outer-space, Nuclear, Medical, Railways, Internet of Things, Information Technology, and other segments. Kaynes’ advanced manufacturing infrastructure enables product manufacturing at variable or flexible volumes across all industrial verticals. Kaynes has contributed electronics modules to the Indian Space Research Organization (ISRO), with the recent successful launch of Chandrayaan 3 (or Moon Expedition) and PSLV-XPoSat.

About DigiLens

DigiLens is a leader in holographic waveguides used for XR displays. The company has developed a patented optical platform and photopolymer technology that deliver best-in-class solutions using a unique, low-cost contact-copy manufacturing process. DigiLens enables OEM partners to design and build XR-enabled devices for the global automobile, enterprise, consumer, avionics, and defense industries. Based in Sunnyvale, CA, DigiLens' investors include industry leaders like Samsung Electronics, Samsung Electro-Mechanics, Diamond Edge Ventures, the strategic investment arm of Mitsubishi Chemical Holdings Corporation, Alsop Louie Partners, Optimas Capital Management, 37 Interactive Entertainment, UDC Ventures, the corporate venture arm of Universal Display Corporation, Niantic, Inc., Sony Innovation Fund, Dolby Family Ventures, Continental AG, and more.



View source version on



Kaynes Technology

Press Contact

Sharath Bhat

President, International Business

+91 9900162366


Press Contact

Brian Hamilton

VP, Sales & Marketing

(610) 721-3956

New Kinaxis Dallas Office Puts the Leading Supply Chain ‘Tech’ in Texas

  Global supply chain innovator bolsters U.S. presence with new Lonestar State location to support ongoing expansion efforts

(BUSINESS WIRE)--Kinaxis® Inc. (TSX: KXS), the leading supply chain management platform, today announced the opening of a new office in Dallas, Texas to help serve the company’s expanding U.S. customer base as it looks to position itself for future growth.

The company already has a well-established team and the new Dallas office located in Las Colinas will serve as a centralized hub where employees and customers can come together to engage, collaborate and work towards solving some of the most pressing challenges facing global supply chains.

The opening of the new Dallas location caps a period of significant growth and expansion for Kinaxis globally, following the addition of offices in the UK, the Netherlands, India, Singapore and Japan, among others. Lockheed Martin is just one of the Dallas-Fort Worth-area companies that utilizes Kinaxis solutions to help them prepare for and respond to disruptions to their vast supply chains.

“Dallas is recognized as a growing, centrally located region for technical and supply chain management talent,” said Megan Paterson, chief operating officer at Kinaxis. “Establishing a permanent hub in the U.S. is a critical part of our global footprint as businesses continue to adopt Kinaxis to manage supply chains in an increasingly complex environment.”

With more than 40,000 users in 100+ countries, Kinaxis works with some of the world’s biggest brands in sectors such as CPG, automotive, high tech, life sciences and more. Its AI-powered technology and patented concurrency technique allows companies to orchestrate their supply chain network end-to-end from strategic planning to last-mile delivery. Kinaxis technology helps supply the agricultural industry with 40% of the world’s tractors, helps keep more than 110,000,000,000 teeth clean each year, and ensures more than 35 million pets are fed nutritious meals each year.

For more information on Kinaxis and current open roles, please visit:

About Kinaxis

Kinaxis is a global leader in modern supply chain management. We serve supply chains and the people who manage them in service of humanity. Our software is trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. We combine our patented concurrency technique with a human-centered approach to AI to empower businesses of all sizes to orchestrate their end-to-end supply chain network, from multi-year strategic planning through down-to-the-second execution and last-mile delivery. For more news and information, please visit or follow us on LinkedIn.


View source version on




Media Relations

Jaime Cook | Kinaxis


Investor Relations

Rick Wadsworth | Kinaxis


Tuesday, January 30, 2024

Xsolla Founder Shurick Agapitov Releases New Book: Once Upon Tomorrow, a Visionary Take on the Metaverse and Its Impact on Global Creativity

 LOS ANGELES - Tuesday, 30. January 2024

(BUSINESS WIRE)--Shurick Agapitov, a visionary author and the Founder of Xsolla unveiled his groundbreaking new book, "Once Upon Tomorrow," today. This pioneering work offers a transformative and aspirational vision of the Metaverse, contrasting markedly with mainstream narratives. Agapitov's book is a thought-provoking journey into the possibilities and potential of the Metaverse, providing a unique perspective diverging from the views often presented at industry conferences and by technology CEOs.

"In 'Once Upon Tomorrow,' I present a vision of the Metaverse as a vast, inclusive, and transformative space. It's not just a digital frontier but a realm where creativity, innovation, and empowerment converge. This book is my invitation to creators, thinkers, and dreamers across the globe to join in shaping a future where technology amplifies human potential and fosters a world of limitless possibilities. The Metaverse, as I see it, is not about control or confinement but about unleashing the collective creativity and entrepreneurial spirit inherent in all of us," said Shurick Agapitov, Founder of Xsolla and acclaimed author of "Once Upon Tomorrow."

"Once Upon Tomorrow" delves into the untapped potential of the Metaverse, highlighting its capacity to unite emerging and legacy brands, create unforgettable consumer experiences, and enrich cultures globally. Agapitov emphasizes the Metaverse's role in democratizing opportunities and equal access to cutting-edge technologies. His vision extends beyond mere technological innovation, underscoring the Metaverse's potential to empower and reward content creators across the globe. The book also highlights the significant impact of the Metaverse on education, offering hope and opportunities for both children and adults worldwide. Agapitov advocates for a decentralized Metaverse moving away from Silicon Valley's dominance, placing control, profit potential, and freedom in the hands of creative communities.

"Once Upon Tomorrow" is more than just a book about the Metaverse; it's a roadmap to a future where technology serves humanity in all its diversity, fostering financial, social, and creative inclusivity. Agapitov envisions a future where every consumer-facing industry, from fashion to healthcare and entertainment, is transformed. The book also explores the potential impact of the Metaverse on business-to-business sectors, education, city planning, inter-government relations, and non-profit efforts.

Agapitov's insight into the evolution of technology, from the early days of Instagram and Snapchat to the future of immersive applications, is a key highlight of the book. He discusses the roles of various technology stakeholders, including internet hosting providers, website developers, cloud computing experts, infrastructure engineers, and the ongoing need for advanced networking and hardware. "Once Upon Tomorrow" is a visionary piece that invites readers to rethink the Metaverse and its limitless potential.

For additional information and to purchase please visit:

About Shurick Agapitov

As the founder of Xsolla, Inc., Shurick Agapitov is a highly respected innovator and advisor in gaming, Web3, Metaverse, and fintech. His trailblazing video game company integrates blockchain technology, providing developers with advanced tools and services for more effective game operations and sales. With a global presence, including offices in Los Angeles, Berlin, and Seoul, Xsolla, under Shurick’s leadership, is shaping the future of gaming and the Metaverse, fostering a more decentralized and inclusive industry.

For additional information about Shurick Agapitov please visit: or

About Xsolla

Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the video game industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Tokyo, and cities around the world, Xsolla supports major gaming titles like Valve, Twitch, Roblox, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.

For additional information and to learn more, please visit:


View source version on



Media Contact

Derrick Stembridge

Global Director of Public Relations, Xsolla

Takeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

 OSAKA, Japan & CAMBRIDGE, Mass. - Tuesday, 30. January 2024

New Indication Delivers on Takeda’s Commitment to Expanding its Broad and Diverse Immunoglobulin (IG) Portfolio to Meet the Needs of People Living with CIDP

Approval Supported by Phase 3 ADVANCE-CIDP Open-label Study Data Demonstrating Safety and Efficacy as an Intravenous Therapy for Adults with CIDP

GAMMAGARD LIQUID [Immune Globulin Infusion (Human) 10% Solution] is the Only Intravenous IG (IVIG) Approved for the Treatment of Multiple Neuromuscular Disorder Indications in the U.S.


(BUSINESS WIRE) -- Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID® [Immune Globulin Infusion (Human) 10% solution] as an intravenous immunoglobulin (IVIG) therapy to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy (CIDP).1 It can be used as induction therapy, which includes an induction dose followed by maintenance doses.1 For treatment of CIDP, GAMMAGARD LIQUID has not been studied in immunoglobulin-naive patients nor as maintenance therapy for periods longer than six months.1

This milestone follows the recent FDA approval of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for maintenance therapy to prevent the relapse of neuromuscular disability and impairment in adults with CIDP.2 HYQVIA is the only combination of immunoglobulin (IG) and hyaluronidase, which makes it a facilitated subcutaneous IG infusion.2

“The approval of GAMMAGARD LIQUID for treatment of CIDP is an encouraging validation of our decades-long commitment to advancing plasma-derived therapies on behalf of people living with rare neuromuscular disorders and bringing our portfolio of differentiated IG therapies to these patients,” said Richard Ascroft, senior vice president and head of Takeda’s U.S. Plasma-Derived Therapies Business Unit. “Together with the recent HYQVIA approval in the U.S., we can now offer induction and maintenance therapy options to adults living with CIDP that may accommodate their personal treatment needs.”

The approval is based on results from a prospective, open-label, single-arm, multicenter clinical study (ADVANCE-CIDP 2) that evaluated the efficacy and safety of GAMMAGARD LIQUID in adults with CIDP who developed a relapse in the randomized, double-blinded, placebo-controlled study evaluating efficacy, safety and tolerability of HYQVIA (ADVANCE-CIDP 1) in adults with CIDP. Efficacy in ADVANCE-CIDP 2 was based on responder rate, where a responder was defined as a subject who demonstrated an improvement of functional disability. The responder rate was 94.4% (N=18, 95% CI: 74.2% to 99.0%). Improvement in grip strength and change in Rasch-built Overall Disability Scale (R-ODS) score were recorded across participants.1

The most common adverse reactions observed in ≥5% of clinical study patients were headache, pyrexia, anemia, leukopenia, neutropenia, illness, blood creatinine increased, dizziness, migraine, somnolence, tremor, nasal dryness, abdominal pain upper, vomiting, chills, nasopharyngitis and pain in extremity.1

CIDP is a rare, acquired, immune-mediated neuromuscular disorder affecting the peripheral nervous system.3,4 It is characterized by progressive, symmetric symptoms such as weakness, tingling or loss of feeling in distal and proximal limbs, loss of reflexes and difficulty walking.3 Because its symptoms may overlap with other rare, neuromuscular conditions, CIDP may be misdiagnosed.5 The mechanism of action of immunoglobulins in the treatment of CIDP in adults has not been fully elucidated but may include immunomodulatory effects.1

“As the standard of care for the treatment of CIDP, IG therapy is thought to help normalize compromised immune systems through immunomodulatory mechanisms,” said Dr. Mamatha Pasnoor, professor in the Department of Neurology at the University of Kansas Medical Center. “Because CIDP is a progressive and complex disease, multiple treatment options are needed, and clinicians now have an additional therapy that can help adults with CIDP manage their disease.”

GAMMAGARD LIQUID is the only IVIG with multiple neuromuscular disorder indications in the U.S. since it is now approved for CIDP and it is the only FDA-approved IVIG to treat multifocal motor neuropathy as a maintenance therapy to improve muscle strength and disability in adults.1 It is also indicated in the U.S. as a replacement therapy for people two years of age or older living with primary immunodeficiency.1


GAMMAGARD LIQUID® [Immune Globulin Infusion (Human) 10% solution] is an intravenous immunoglobulin (IVIG) that is infused into the veins. GAMMAGARD LIQUID is approved in the U.S. as an IG therapy to improve neuromuscular disability and impairment in adult patients with CIDP, as a replacement therapy for primary immunodeficiency (PI) in adult and pediatric patients two years of age and older, and as a maintenance therapy to improve muscle strength and disability in adult patients with multifocal motor neuropathy (MMN). Also known as KIOVIG outside the U.S. and Canada, it is approved in 66 countries worldwide.


HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is a liquid medicine containing Recombinant Human Hyaluronidase and immunoglobulin (IG) and is approved in the U.S. to treat adults and children two years of age and older with primary immunodeficiency (PI), and as maintenance therapy to prevent relapse of neuromuscular disability and impairment in adult patients with CIDP. It is also approved by the European Medicines Agency (EMA) as a replacement therapy in adults, children and adolescents with PI and with secondary immunodeficiency (SID) who suffer from severe or recurrent infections, ineffective antimicrobial treatment, and either proven specific antibody failure (PSAF) or serum IgG level of <4 g/L. HYQVIA is infused under the skin into the fatty subcutaneous tissue. HYQVIA contains IG collected from human plasma. IG are antibodies that maintain the body’s immune system. The hyaluronidase part of HYQVIA facilitates the dispersion and absorption of IG in the subcutaneous space between the skin and the muscle. HYQVIA is infused up to once a month (every two, three or four weeks for CIDP; every three or four weeks for PI).


ADVANCE-CIDP 2 was a prospective, open-label, single-arm, multicenter clinical study that evaluated the efficacy and safety of GAMMAGARD LIQUID in adults with CIDP who developed a relapse in the randomized, double-blinded, placebo-controlled study evaluating efficacy, safety and tolerability of HYQVIA (ADVANCE-CIDP 1) in adults with CIDP. The 18 patients who relapsed during ADVANCE-CIDP 1 were offered enrollment in ADVANCE-CIDP 2.

GAMMAGARD LIQUID was administered at an induction dose of 2 g/kg body weight, followed by maintenance infusions at every three weeks for a period of six months. The dose of GAMMAGARD LIQUID treatment could be adjusted at the investigator's discretion. Adjustments to the dosing interval of every three weeks were not allowed. All subjects completed the study. All dosed subjects were analyzed for efficacy and safety. Efficacy of ADVANCE-CIDP 2 was based on responder rate, where a responder is defined as subjects who had at least a one-point decrease in the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score at the completion of the treatment period (six months). The responder rate was 94.4% (N=18, 95% CI: 74.2% to 99.0%). The INCAT score returned to baseline values prior to joining the study in 17 of the 18 subjects (94.4%) at six months. All subjects had improvement in functional ability as defined by a composite outcome metrics that included INCAT score, grip strength, or Rasch-built Overall Disability Scale (R-ODS) score.

Further information about the ADVANCE-CIDP 2 study is available at under study identifier NCT02549170.


GAMMAGARD LIQUID is indicated as replacement therapy for Primary Humoral Immunodeficiency (PI) in adult and pediatric patients ≥2 years, as a maintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN), and as a therapy to improve neuromuscular disability and impairment in adult patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

LIMITATIONS OF USE (CIDP): GAMMAGARD LIQUID has not been studied in immunoglobulin-naive patients with CIDP. GAMMAGARD LIQUID maintenance therapy in CIDP has not been studied for periods longer than 6 months. After responding during an initial treatment period, not all patients require indefinite maintenance therapy with GAMMAGARD LIQUID in order to remain free of CIDP symptoms. Individualize the duration of any treatment beyond 6 months based upon the patient’s response and demonstrated need for continued therapy.

HYQVIA is indicated for the treatment of Primary Immunodeficiency (PI) in adults and pediatric patients two years of age and older and for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment in adults.

HYQVIA is for subcutaneous use only. 

GAMMAGARD LIQUID for PI is for intravenous or subcutaneous use. 

GAMMAGARD LIQUID for MMN and CIDP is for intravenous use only.




Thrombosis may occur with immune globulin (IG) products, including HYQVIA and GAMMAGARD LIQUID. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.

For patients at risk of thrombosis, administer HYQVIA and GAMMAGARD LIQUID at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration.

Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.



Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients with immune globulin intravenous (IGIV) products, including GAMMAGARD LIQUID. Patients predisposed to renal dysfunction include those with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. GAMMAGARD LIQUID does not contain sucrose.


HYQVIA and GAMMAGARD LIQUID are contraindicated in patients with a history of anaphylactic or severe systemic hypersensitivity reactions to human IG, and IgA-deficient patients with antibodies to IgA and a history of hypersensitivity to human IG. Anaphylaxis has been reported with intravenous (IV) use of GAMMAGARD LIQUID.

Additionally, HYQVIA is contraindicated in patients with known systemic hypersensitivity to hyaluronidase including Recombinant Human Hyaluronidase of HYQVIA, and known systemic hypersensitivity to human albumin (in the hyaluronidase solution).

Warnings and Precautions 

Hypersensitivity: Severe hypersensitivity reactions may occur, even in patients who have tolerated previous treatment with human IG. If a hypersensitivity reaction occurs, discontinue infusion immediately and institute appropriate treatment. IgA-deficient patients with antibodies to IgA are at greater risk of developing potentially severe hypersensitivity reactions, including anaphylaxis.

Renal Dysfunction/Failure: Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, and death may occur with IV use of IG products, especially those containing sucrose. Acute renal dysfunction/failure has been reported in association with infusions of GAMMAGARD LIQUID. Ensure patients are not volume depleted prior to infusion. In patients at risk due to pre-existing renal insufficiency or predisposition to acute renal failure, assess renal function before initiation and throughout treatment, and consider lower, more frequent dosing. If renal function deteriorates, consider discontinuation.

Thrombosis: Has been reported to occur following treatment with IG products, including HYQVIA and in the absence of known risk factors. In patients at risk, administer at the minimum dose and infusion rate practicable. Ensure adequate hydration before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

Aseptic Meningitis Syndrome: Has been reported with use of IG, including HYQVIA and may occur more frequently in females. Conduct a thorough neurological exam on patients exhibiting signs and symptoms, to rule out other causes of meningitis. Discontinuing IG treatment has resulted in remission within several days without sequelae. The syndrome usually begins within several hours to two days following IG treatment.

Hemolysis: HYQVIA and GAMMAGARD LIQUID contain blood group antibodies, which may cause a positive direct antiglobulin reaction and hemolysis. Monitor patients for signs and symptoms of hemolysis and delayed hemolytic anemia and, if present, perform appropriate confirmatory lab testing.

Transfusion-Related Acute Lung Injury: Non-cardiogenic pulmonary edema has been reported with IV-administered IG, including GAMMAGARD LIQUID. Monitor patients for pulmonary adverse reactions. If suspected, perform appropriate tests for presence of anti-neutrophil and anti-HLA antibodies in both product and patient serum. May be managed using oxygen therapy with adequate ventilatory support.

Transmittable Infectious Agents: Because HYQVIA and GAMMAGARD LIQUID are made from human plasma, they may carry a risk of transmitting infectious agents (e.g., viruses, other pathogens). No confirmed cases of viral transmission of variant Creutzfeldt-Jakob disease (vCJD) have been associated with GAMMAGARD LIQUID, and no cases have been associated with HYQVIA.

Interference with Lab Tests: False positive serological test results and certain assay readings, with the potential for misleading interpretation, may occur as the result of passively transferred antibodies.

Additional Warnings and Precautions for HYQVIA 

Immunogenicity of Recombinant Human Hyaluronidase (rHuPH20): Non-neutralizing antibodies to the Recombinant Human Hyaluronidase component can develop. The clinical significance of these antibodies or whether they interfere with fertilization in humans is unknown.

Spread of Localized Infection: Do not infuse HYQVIA into or around an infected area due to potential risk of spreading a localized infection.

Additional Warnings and Precautions for GAMMAGARD LIQUID 

Hyperproteinemia, increased serum viscosity, and hyponatremia may occur. It is critical to distinguish true hyponatremia from a pseudohyponatremia because certain treatments may lead to volume depletion, a further increase in serum viscosity, and a predisposition to thromboembolic events.

Adverse Reactions 


The most common adverse reactions observed in >5% of patients in the clinical trials were: 

PI: local adverse reactions including pain, erythema, edema, and pruritus, and systemic adverse reactions including, headache, antibody formation against Recombinant Human Hyaluronidase (rHuPH20), fatigue, nausea, pyrexia, and vomiting. 

CIDP: local reactions, headache, pyrexia, nausea, fatigue, erythema, pruritus, increased lipase, abdominal pain, back pain, and pain in extremity.


The most serious adverse reactions observed in clinical studies in PI was aseptic meningitis, and in MMN were pulmonary embolism and blurred vision.

The most common adverse reactions observed in ≥5% of patients in the clinical trials were: 

IV administration for PI: Headache, fatigue, pyrexia, nausea, chills, rigors, pain in extremity, diarrhea, migraine, dizziness, vomiting, cough, urticaria, asthma, pharyngolaryngeal pain, rash, arthralgia, myalgia, oedema peripheral, pruritus, and cardiac murmur. 

Subcutaneous administration for PI: Infusion site (local) event (rash, erythema, edema, hemorrhage, and irritation), headache, fatigue, heart rate increased, pyrexia, abdominal pain upper, nausea, vomiting, asthma, blood pressure systolic increased, diarrhea, ear pain, aphthous stomatitis, migraine, oropharyngeal pain, and pain in extremity. 

IV administration for MMN: Headache, chest discomfort, muscle spasms, muscular weakness, nausea, oropharyngeal pain, and pain in extremity. 

IV administration for CIDP: Headache, pyrexia, anemia, leukopenia, neutropenia, illness, blood creatinine increased, dizziness, migraine, somnolence, tremor, nasal dryness, abdominal pain upper, vomiting, chills, nasopharyngitis, and pain in extremity.

Drug Interactions 

Passive transfer of antibodies may transiently interfere with the immune responses to live attenuated virus vaccines (e.g., measles, mumps, rubella, and varicella).

Use In Specific Populations 

Pregnancy: Limited human data are available on the use of HYQVIA during pregnancy. The effects of antibodies to the Recombinant Human Hyaluronidase on the human embryo or fetal development are unknown. It is not known whether HYQVIA can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity. HYQVIA should be given to a pregnant woman only if clearly needed.

For Full U.S. Prescribing Information for GAMMAGARD LIQUID, please visit:

For Full U.S. Prescribing Information for HYQVIA, please visit:

About Takeda 

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit

Important Notice 

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements 

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: or at Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical Information 

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.


1 GAMMAGARD LIQUID® [Immune Globulin Infusion (Human) 10% solution] U.S. Prescribing Information.

2 HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] U.S. Prescribing Information.

3 Dalakas MC. Nat Rev Neurol. 2011;7(9):507–17. 

4 GBS CIDP Foundation International. Voice of the Patient Report. August 26, 2022. Accessed August 2022. 

5 Broers MC, Bunschoten C, Nieboer D, Lingsma HF, Jacobs BC. Eur J Neurol. 2021;28(6):2065-2073.


View source version on



International Media

Lauren Padovan

+1 (617) 431-8028

U.S. Media

Courtney Winger

+1 (617) 301-0687